Affiliation:
1. Beijing An Zhen Hospital: Capital Medical University Affiliated Anzhen Hospital
Abstract
Abstract
Background
The prognostic value of hibernating myocardium (HM) and left ventricular (LV) remodeling in patients with ischemic heart failure (IHF) and diabetes mellitus (DM) remains undetermined. Therefore, we aimed to evaluate the prognostic value of HM and LV remodeling in such patients.
Methods
A total of 333 consecutive patients with coronary artery disease (CAD) and LV ejection fraction ≤ 35% who underwent gated 99mTc-MIBI single photon emission computed tomography (SPECT) myocardial perfusion imaging (G-MPI) and gated 18F-FDG positron emission tomography (PET) myocardial metabolic imaging at Beijing Anzhen Hospital between April 2016 and February 2019 were enrolled and followed up for a median of 3.6 (range, 0.3–5.1) years. Patients were divided into DM (n = 141) and non-DM (n = 192) groups. HM + was defined as HM > 10%. LV remodeling + was defined as end-systolic volume index ≥ 92 mL/m2 by G-MPI. The endpoint was all-cause death.
Results
More HM was observed in DM than that in non-DM group (18.0 [10.0, 27.0]% vs. 10.0 [0.5, 20.0]%, P < 0.001, respectively). In DM patients, survival for patients with LV remodeling was lower than that for those without LV remodeling (55.1% ± 10.0% vs. 79.9% ± 7.1%, P = 0.007, respectively), but there was no significant difference in survival between HM + and HM- (P > 0.05). Revascularization was associated with better long-term survival than medical therapy in patients with HM+ (DM+, 87.1% ± 7.6% vs. 45.3% ± 10.4%; DM-, 95.7% ± 2.9% vs. 41.9% ± 10.7%, all P value < 0.001), or LV remodeling+ (DM+, 95.2% ± 4.6% vs. 40.3% ± 10.9%, P = 0.001; DM-, 87.1% ± 9.6% vs. 52.3% ± 8.7%, P = 0.004).
Conclusions
HM may be more prevalent in IHF patients with DM compared with those non-DM. Assessing HM and LV remodeling using nuclear imaging techniques allowed for risk stratification and guided strategy decision-making in DM patients.
Publisher
Research Square Platform LLC
Reference44 articles.
1. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC;McDonagh TA;Rev Esp Cardiol (Engl Ed),2022
2. Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes;Park JJ;Diabetes Metab J,2021
3. Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future;Liang P;Curr Stem Cell Res Ther,2021
4. Global estimates of diabetes prevalence for 2013 and projections for 2035;Guariguata L;Diabetes Res Clin Pract,2014
5. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology;Seferović PM;Eur J Heart Fail,2018